TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35956412
Drug: Study formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study formulation + eye lubricant (A + L)
Study: 35956412
Drug: Placebo +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo + eye lubricant (P + L)
Study: 35866833
Drug: nab-paclitaxel plus
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: nab-paclitaxel plus gemcitabine (first-line chemotherapy)
Study: 33639007
Drug: Proximal nontouch
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Proximal nontouch biofield therapy
Study: 35565731
Drug: Resveratrol 75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resveratrol 75 mg twice daily for three months
Study: 33379851
Drug: Single Negative
Normalized name: GLYCERIN NEGATIVE CONTROL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single Negative Pressure Therapy (SNPT)
Study: 33379851
Drug: Cyclic Alternating
Normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclic Alternating Negative Pressure Therapy (CANPT)
Study: 33138628
Drug: Rivaroxaban 2.5
Normalized name: rivaroxaban 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban 2.5 mg twice daily plus 100 mg aspirin daily
Study: 35585282
Drug: Atorvastatin 10
Normalized name: atorvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 10 mg for 24 weeks
Study: 35596117
Drug: ACT-1014-6470 (0.5-200
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACT-1014-6470 (0.5-200 mg)
Study: 35596117
Drug: ACT-1014-6470 (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACT-1014-6470 (10 mg) under fasted conditions
Study: 33151286
Drug: Indoximod plus
Normalized name: Indoximod
DrugBank: Indoximod (DB12827)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indoximod plus taxane (paclitaxel 80 mg/m2 weekly or docetaxel 75 mg/m2 every 3 weeks)
Study: 33151286
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus taxane (paclitaxel 80 mg/m2 weekly or docetaxel 75 mg/m2 every 3 weeks)
Study: 33444206
Drug: Personalised dietary
Normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Personalised dietary advice and protein-enriched food products to increase protein intake to at least 1.2 g/kg adjusted BW/day
Study: 33444206
Drug: Personalised dietary
Normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Personalised dietary advice and protein-enriched food products plus advice to consume 7.5-10 g protein through protein-enriched foods within half an hour after usual physical activity
Study: 33354268
Drug: At-home local
Normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: At-home local vibration therapy (LVT) with NOVAFON Pro Sk2/2: 50/100 Hz, applied bilaterally for 16 minutes daily for 1 week
Study: 35400584
Drug: Emibetuzumab plus
Normalized name: Emibetuzumab
DrugBank: Emibetuzumab (DB11849)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emibetuzumab plus Erlotinib (750 mg every 2 weeks + 150 mg once daily)
Study: 35400584
Drug: Emibetuzumab monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emibetuzumab monotherapy (750 mg every 2 weeks)
Study: 35400584
Drug: Emibetuzumab monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emibetuzumab monotherapy
Study: 34825590
Drug: Buddy-style intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buddy-style intervention (5-10 min weekly)
Study: 35738778
Drug: Single-dose ivermectin
Normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single-dose ivermectin (12 mg)
Study: 35738778
Drug: Double-dose ivermectin
Normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Double-dose ivermectin (24 mg)
Study: 32052907
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of combination formulation of vitamin C, vitamin E, and ferulic acid after Q-switched Nd:YAG laser treatment
Study: 35791276
Drug: Cardiac resynchronization
Normalized name: Leonurus cardiaca extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardiac resynchronization therapy (CRT) upgrade
Study: 34610611
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline injected and patient‐controlled analgesic pump used (Control)
Study: 32240186
Drug: Peer mentoring
Normalized name: IRRIGATOR,GREER MENTOR #6004
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peer mentoring program with monthly one-on-one and group sessions
Study: 34427475
Drug: Mechanical thrombectomy
Normalized name: PIPERONYL BUTOXIDE TECHNICAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mechanical thrombectomy with the detachable Solitaire thrombectomy device and best medical therapy (BMT)
Study: 35614161
Drug: Oral metronomic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral metronomic chemotherapy (OMC) with celecoxib 200 mg twice daily and methotrexate 15 mg/m2 weekly for 12 months
Study: 35614161
Drug: Oral metronomic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral metronomic chemotherapy (OMC)
Study: 34446053
Drug: Short course
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short course radiotherapy (25 Gray in 5 fractions over one week) with concomitant durvalumab (1500 mg every 4 weeks), followed by FOLFOX (85 mg/m2 oxaliplatin, 350 mg folinic acid, and 400 mg/m2 bolus 5-FU on day 1, followed by 2400 mg/m2 5-FU infusion over 46-48 hours, every 2 weeks) and durvalumab.
Study: 34446053
Drug: Long course
Normalized name: long pepper extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long course chemoradiotherapy (50 Gray to primary tumour in 25 fractions over 5 weeks with concomitant oral capecitabine 825 mg/m2 twice per day on days of radiotherapy) with durvalumab followed by FOLFOX and durvalumab.
Study: 36196729
Drug: Liraglutide (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liraglutide (3 mg) + Metformin (2x1,000 mg)
Study: 36196729
Drug: Metformin monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin monotherapy (2x1,000 mg)
Study: 32179067
Drug: Psychoeducation‐based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychoeducation‐based cognitive rehabilitation intervention delivered in a group setting during 6 weekly 2.5‐hour classes.
Study: 36403975
Drug: Fascia iliaca
Normalized name: OCTINOXATE .012 mL in 6 mL / OCTISALATE .12 mL in 6 mL TOPICAL CREAM [RIMMEL LONDON MOISTURE RENEW LIPGLOSS - FUSCIA THERAPHY (345)]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fascia iliaca block (FIB) with 30 mL of 0.185% ropivacaine
Study: 32556602
Drug: Adavosertib (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adavosertib (300 mg) in fed state (high-fat, high-calorie meal)
Study: 32556602
Drug: Adavosertib (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adavosertib (300 mg) in fasted state
Study: 34446531
Drug: rhTNK‐tPA 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhTNK‐tPA 0.25 mg/kg (single bolus) to a maximum of 25 mg
Study: 34446531
Drug: rt‐PA 0.9
Approvals — FDA: no, EMA: no, PMDA: no
Description: rt‐PA 0.9 mg/kg (10% bolus + 90% infusion/1 hour) to a maximum of 90 mg
Study: 32155622
Drug: Preoperative oral
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative oral carbohydrate (POC)
Study: 36131360
Drug: Co-administration of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-administration of SHR4640 and febuxostat
Study: 32513359
Drug: Ointment containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ointment containing Polymyxin B and Bacitracin (Group A, n=28)
Study: 35762293
Drug: Mexiletine (333
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mexiletine (333 mg)
Study: 35762293
Drug: Lacosamide (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lacosamide (300 mg)
Study: 33545096
Drug: Azithromycin 500
Normalized name: azithromycin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin 500 mg once per day by mouth or intravenously for 10 days or until discharge
Study: 32423239
Drug: SHP465 MAS
Normalized name: Zhi ma oil
DrugBank: Sesame oil (DB11172)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHP465 MAS (12.5-75 mg)
Study: 32423239
Drug: SHP465 MAS
Normalized name: Zhi ma oil
DrugBank: Sesame oil (DB11172)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHP465 MAS (25, 50, or 75 mg)
Study: 35276662
Drug: Training Group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Training Group (TG) - variable practice training with weighted wrist bands, twice a week for 1 month
Study: 36346079
Drug: Bepirovirsen 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bepirovirsen 300 mg weekly for 24 weeks (group 1)
Study: 36346079
Drug: Bepirovirsen 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bepirovirsen 300 mg for 12 weeks then 150 mg for 12 weeks (group 2)
Study: 36346079
Drug: Bepirovirsen 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bepirovirsen 300 mg for 12 weeks then placebo for 12 weeks (group 3)
Study: 36346079
Drug: Placebo for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for 12 weeks then Bepirovirsen 300 mg for 12 weeks (group 4)
Study: 36346079
Drug: Bepirovirsen 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bepirovirsen 300 mg weekly for 24 weeks
Study: 32729802
Drug: Inoculated with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inoculated with 10 μL of zoospore suspension (2 × 105 zoospore/ml)
Study: 33030064
Drug: Drug adjustment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug adjustment
Study: 33876439
Drug: Chronic use
Normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chronic use of RAAS blockers
Study: 33876439
Drug: Non-use of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-use of RAAS blockers
Study: 32610608
Drug: Leucine-Enriched Amino
Normalized name: Leucine
DrugBank: Leucine (DB00149)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Leucine-Enriched Amino Acid Supplement with breakfast
Study: 32610608
Drug: Leucine-Enriched Amino
Normalized name: Leucine
DrugBank: Leucine (DB00149)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Leucine-Enriched Amino Acid Supplement post-exercise
Study: 32548951
Drug: Exposure-long (EXP-L)
Normalized name: long pepper extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exposure-long (EXP-L)
Study: 32548951
Drug: Exposure treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exposure treatments (EXP)
Study: 36039506
Drug: Individual cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual cognitive processing therapy (CPT)
Study: 36039506
Drug: Group cognitive
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group cognitive processing therapy (CPT)
Study: 34034897
Drug: Implant-retained removable
Normalized name: betaine
DrugBank: Betaine (DB06756)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Implant-retained removable dentures
Study: 34363999
Drug: Antidepressant treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant treatment (3 commonly prescribed antidepressants)
Study: 34604936
Drug: Laser-microgrooved implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laser-microgrooved implants with laser-microgrooved prosthetic abutments
Study: 34604936
Drug: Laser-microgrooved implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laser-microgrooved implants with machined prosthetic abutments
Study: 33975553
Drug: GnRH antagonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH antagonist protocol (fresh transfer cycles)
Study: 33975553
Drug: Depot GnRH
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Depot GnRH agonist protocol (fresh transfer cycles)
Study: 33975553
Drug: GnRH antagonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH antagonist protocol (frozen-thawed transfer cycles)
Study: 33975553
Drug: Depot GnRH
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Depot GnRH agonist protocol (frozen-thawed transfer cycles)
Study: 38258274
Drug: Prednisolone 5
Normalized name: prednisolone 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone 5 mg
Study: 33302704
Drug: Interpersonal and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interpersonal and social rhythm therapy (with or without cognitive remediation)
Study: 32070309
Drug: Postoperative chemoradiotherapy
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative chemoradiotherapy (POCRT) with 50.4 Gy concurrent with paclitaxel (135-150 mg/m2) plus cisplatin or nedaplatin (50-75 mg/m2) every 28 days for two cycles.
Study: 32070309
Drug: Postoperative radiotherapy
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative radiotherapy (PORT) with a prescription dose of 54 Gy.
Study: 33153439
Drug: 20 Hz
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 Hz vibration therapy for 20 weeks, 9 min per day, 4 times a week
Study: 33153439
Drug: 25 Hz
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 Hz vibration therapy for 20 weeks, 9 min per day, 4 times a week
Study: 35247334
Drug: Topical LHA510
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical LHA510 (twice a day for 8 weeks, then 3 times a day for 4 weeks)
Study: 34346266
Drug: IND/MF high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: IND/MF high-dose (150/320 μg)
Study: 34346266
Drug: IND/MF medium-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: IND/MF medium-dose (150/160 μg)
Study: 34346266
Drug: SAL/FLU high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAL/FLU high-dose (50/500 μg)
Study: 33755779
Drug: Regular treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular treatment and medical consultations for residents with Parkinson's disease
Study: 35277011
Drug: RLX2™ containing
Approvals — FDA: no, EMA: no, PMDA: no
Description: RLX2™ containing alpha‐s1‐casein tryptic hydrolysate and L‐theanine
Study: 33278754
Drug: Routine care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine care and treatment practices without family presence
Study: 34780993
Drug: Physical placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical placebo administered to the own, physical body
Study: 33631102
Drug: Microbial Ecosystem
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Microbial Ecosystem Therapeutic 2 (MET‐2); initial daily treatment of 10 oral capsules for 2 days, then 3 capsules for 8 days; higher dose if recurrence: 20 capsules for 2 days, then 3 capsules for 8 days.
Study: 35779302
Drug: Intranasal dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal dexmedetomidine (2 μg/kg)
Study: 32147060
Drug: Fenugreek seed
Normalized name: FENUGREEK SEED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenugreek seed (FS) supplementation (5 g FS powder, 3 times a day)
Study: 32147060
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (anti-diabetic drugs and nutritional consults)
Study: 33347020
Drug: Aripiprazole (high
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aripiprazole (high and low doses)
Study: 34836088
Drug: Single-dose intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose intake of 1.3 g of polyphenol-rich cocoa powder
Study: 34836088
Drug: Daily consumption
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily consumption of 1.3 g of polyphenol-rich cocoa powder for 28 days
Study: 34836088
Drug: Single-dose intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose intake and sustained supplementation
Study: 35085249
Drug: Buprenorphine (target
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine (target concentrations of 0.5 ng/mL in healthy volunteers)
Study: 34217164
Drug: Nerve block
Normalized name: Nerve Block Tray 22g
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nerve block therapy (Control)
Study: 37980922
Drug: Step-up treatment
Normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Step-up treatment
Study: 35860186
Drug: Lateral L-shaped
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lateral L-shaped incision approach (Control)
Study: 34803872
Drug: Remote ischemic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remote ischemic conditioning (RIC) plus standard medical therapy
Study: 33369276
Drug: Repository corticotropin
Normalized name: Repository Corticotropin Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repository corticotropin injection 40 IU subcutaneously twice weekly for 15 days
Study: 33369276
Drug: Repository corticotropin
Normalized name: Repository Corticotropin Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repository corticotropin injection 80 IU subcutaneously twice weekly for 15 days
Study: 33369276
Drug: Repository corticotropin
Normalized name: Repository Corticotropin Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repository corticotropin injection 80 IU subcutaneously 3 times weekly for 15 days
Study: 33369276
Drug: Synthetic ACTH1‐24
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synthetic ACTH1‐24 depot 0.5 mg subcutaneously for 5 days
Study: 33369276
Drug: Synthetic ACTH1‐24
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synthetic ACTH1‐24 depot 0.75 mg subcutaneously for 5 days
Study: 33369276
Drug: Synthetic ACTH1‐24
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synthetic ACTH1‐24 depot 1 mg subcutaneously for 5 days
Study: 33369276
Drug: Synthetic ACTH1‐24
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synthetic ACTH1‐24 depot 1 mg intramuscularly for 5 days
Study: 33414435
Drug: Cortisol (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cortisol (20 mg) administered orally 1 hour before exposure sessions
Study: 33414435
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered orally 1 hour before exposure sessions
Study: 32280055
Drug: 45 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 45 g/day of high‐amylose maize (RS2) for 12 weeks
Study: 33517896
Drug: Inhaled high
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled high molecular weight hyaluronan (HMW-HA)
Study: 36456969
Drug: Electroacupuncture (EA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electroacupuncture (EA) treatment combined with routine treatment
Study: 36456969
Drug: Routine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine treatment (medication and rehabilitation)
Study: 32737923
Drug: Insulin Lispro
Normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin Lispro (LIS)
Study: 35863836
Drug: Low-dose trimethoprim-sulfamethoxazole
Normalized name: sulfamethoxazole / trimethoprim
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose trimethoprim-sulfamethoxazole (10 mg/kg/day of TMP)
Study: 35863836
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care trimethoprim-sulfamethoxazole (15 mg/kg/day of TMP)
Study: 32902647
Drug: Androgen deprivation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Androgen deprivation therapy (ADT) during radiotherapy
Study: 32902647
Drug: Radiotherapy without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radiotherapy without androgen deprivation therapy (ADT)
Study: 35810336
Drug: Exercise intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exercise intervention (high‐intensity interval exercise at 80% of VO2max, with 1‐minute high‐intensity intervals at 95% of VO2max, twice a week for 3 months)
Study: 35429480
Drug: Ganaxolone (maximum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ganaxolone (maximum dose 63 mg/kg per day for patients weighing ≤28 kg or 1800 mg/day for patients weighing >28 kg)
Study: 36418565
Drug: DHA-supplement (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA-supplement (250 mg/day)
Study: 36418565
Drug: DHA-supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA-supplement
Study: 34157024
Drug: six weekly
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: six weekly group-format stroke risk reduction self-management training sessions
Study: 34157024
Drug: enhanced treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: enhanced treatment control (information on cardiovascular risk)
Study: 32171028
Drug: Comprehensive medication
Normalized name: Easy Care First Aid Kit - Comprehensive KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comprehensive medication reviews (CMRs) during hospital stay
Study: 32171028
Drug: Comprehensive medication
Normalized name: Easy Care First Aid Kit - Comprehensive KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comprehensive medication reviews (CMRs) post-discharge
Study: 32171028
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no comprehensive medication reviews)
Study: 35850961
Drug: 20-30 mg
Normalized name: vilazodone
DrugBank: Vilazodone (DB06684)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20-30 mg oral sustained-release morphine daily for 4 weeks
Study: 33109480
Drug: Contemporary neuroscience
Normalized name: capsaicin
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Contemporary neuroscience approach (pain neuroscience education, stress management, cognition-targeted exercise therapy)
Study: 33109480
Drug: Conventional physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional physical therapy (biomedically focused education, graded and active exercise therapy)
Study: 35478103
Drug: Group A:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A: 50 μg misoprostol escalated to 100 μg and then to 200 μg every 4 h (max 600 μg daily)
Study: 35478103
Drug: Group B:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B: 25 μg misoprostol followed by 100 μg every 4 h (max 300 μg daily)